Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilostazol added to risperidone for children with autism
IRCT20090117001556N124Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of cilostazol in Autism Spectrum Disorder (ASD) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Severity of autism. Started May 2020; status: completed.
02
Drugs
cilostazol
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on IRCT20090117001556N124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090117001556N124.